Core Viewpoint - The event "Innovation Source, Health Navigation" highlights Beijing's strategic focus on the pharmaceutical and health sectors, showcasing the city's efforts to drive high-quality economic development through innovation and clinical needs [1][3][19]. Group 1: Event Overview - The event was organized by the Beijing Municipal Cyberspace Administration and featured a visit to various innovative pharmaceutical companies and research centers [1][2]. - The media delegation explored the complete path of innovative drugs from target discovery to clinical approval, emphasizing the importance of clinical needs and policy support in driving pharmaceutical innovation [2][3]. Group 2: Industry Development - The Zhongguancun Life Science Park has become a hub for innovation in China's life sciences, housing over 1,000 innovative pharmaceutical companies and several national-level research institutions [3][4]. - The park includes significant medical facilities with over 3,000 beds, supporting clinical research and the development of innovative drugs and medical devices [3]. Group 3: Company Highlights - Wantaibio invests over 1 billion yuan annually in R&D, with over 30% of its workforce dedicated to research, resulting in hundreds of innovative products, including six global firsts [12]. - Huahui Anjian focuses on developing competitive innovative drugs in virology and oncology, with several drugs in different clinical development stages, including a breakthrough therapy for hepatitis B [14]. - Nuo Cheng Jian Hua has over ten innovative drugs in clinical stages, with significant trials ongoing in China and globally, including a BTK inhibitor and a humanized monoclonal antibody [16][18]. Group 4: Innovation Ecosystem - The event emphasized the importance of a supportive research policy and industrial ecosystem in Beijing, which provides fertile ground for the growth of innovative pharmaceutical companies [19]. - The ongoing monthly thematic visits aim to promote the achievements of high-quality economic development in Beijing, focusing on key sectors such as advanced manufacturing and biomedicine [19].